Cancer molecular Dx firm seeks to obtain $6.6 million

12/24/2012 | GenomeWeb Daily News (free registration)

Epigenomics hopes to obtain $6.6 million in a funding round it plans to launch next month. The company is the maker of the Epi proColon test, a blood-based assay for screening colorectal cancer. Proceeds from the planned fundraising will be used to finance the company's operations as well as expand its capabilities for product distribution.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ